Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

NCT04984980 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Carcinoma
Initially Unresectable

Interventions

DRUG: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab

Sponsor

Fudan University